Geoff is a highly experienced, global CFO. He has demonstrated an ability to build, lead and develop finance, legal, tax and systems teams and organisations to perform, support and enhance sustainable, highly profitable growth with high EBITDA to cash conversion.
Geoff provides strong strategic thinking to anticipate and implement change in demanding Private Equity environments with equity stakeholders such as Astorg and Goldman Sachs as well as with key lenders such as Alcentra, KKR and Halcyon and many others in a > € 400 million financing rated by Moodys and by S&P.
He has played a key role in transformational M&A activity with the acquisitions of Compeed from J&J, of Rare Disease assets from BMS and Mederma from Merz for an aggregate consideration exceeding € 700 million. Geoff played too a major role in the sale of HRA from private ownership to private equity in 2016 and then to Perrigo in 2022 for € 1.8 billion, generating strong returns for all stakeholders.